Drug Target Review

APRIL 17, 2024

Dr Chowell spent a year as a visiting graduate student at the Moe Win Laboratory for Information and Decision Systems at MIT. During residency, he conducted laboratory research with Dr Timothy Chan investigating predictors of response to immunotherapy as part of the American Board of Radiology Holman Research pathway.

Immune Response 105

Immune Response Laboratories DNA Virus 105

Broad Institute

AUGUST 31, 2023

Now researchers at the Broad Institute of MIT and Harvard have used cutting-edge continuous laboratory evolution and engineering methods to develop improved versions of the gene-editing tool. What had not been done until now is improving the reverse transcriptase in a way that’s tailor-made for prime editing.”

DNA 145

DNA RNA Engineering Laboratories 145

Agency IQ

JULY 26, 2024

reference laboratories for high-risk diagnostics The newly available May 2024 meetings of the Medical Device Coordination Group provide insight into the European Commission’s efforts to fully implement the European medical device and diagnostic regulations. Reference Laboratories: E.U. Top IVDR Notified Body concern: Lack of E.U.

Laboratories 40

Laboratories Regulations Virus Production 40

The Pharma Data

NOVEMBER 27, 2020

UK firm develops solution for identifying whether patients are actually infectious from a virus or not. Iceni Diagnostics has revealed it is developing a new technology that can disclose if patients are actually infectious with a live virus or not. Read on to for the full insight.

Vaccine 52

Vaccine Virus International Immune Response 52

The Pharma Data

JANUARY 6, 2021

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ sangivamycin) has broad-spectrum antiviral activity in laboratory-based assays against several viruses. ROCHESTER, N.Y. , 7, 2021 /PRNewswire/ — OyaGen, Inc. Bennett et al., About OYA1. OYA1 (a.k.a.

Virus 40

Virus Clinical Trials Government Laboratories 40

The Pharma Data

SEPTEMBER 17, 2020

A rapid test can accurately diagnose a coronavirus infection within 90 minutes without needing a specialist laboratory, say scientists. The device is already being used in eight NHS hospitals to quickly identify patients who are carrying the virus. ” If the lab tests said the patient was free of the virus, so did the rapid test.

Virus 52

Virus Laboratories Hospitals Research 52

SCIENMAG: Medicine & Health

OCTOBER 18, 2023

This study is conducted by the Jiangsu Provincial Center for Disease Control and Prevention, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Vaccines for Infectious Diseases of Xiamen University, China National Institutes for Food and Drug Control, and Xiamen Innovax Biotech Company.

Vaccine 52

Vaccine Laboratories Virus Science 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

PerkinElmer

MAY 28, 2020

Unfortunately, the road towards treatment can be time-consuming, especially when utilizing assays with live virus. The handling of these pathogens needs to take place in research laboratories that are designated as biosafety level 3 or higher due to its dangerous infectious nature.

Vaccine 52

Vaccine Disease Virus Small Molecule 52

Drug Target Review

DECEMBER 5, 2024

Challenges of viral capsids in gene therapy efficiency A widely used production method of rAAV vectors requires co-transfection of host cell lines with three plasmids, including one carrying the transgene of interest, one carrying the capsid and replication sequences, and a helper virus to circumvent the inability of rAAV to self-amplify.

Therapies 52

Therapies Virus DNA Compliance 52

PerkinElmer

JULY 13, 2020

The complex relationship between a virus and its host is one of the hottest topics in science right now, and has been given considerable attention in recent weeks as a result of the race to understand the virus that causes COVID-19 and its potential vulnerabilities.

RNA 52

RNA Virus Laboratories Science 52

The Pharma Data

APRIL 15, 2022

Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. The top protein neutralized the virus with similar or greater potency than antibody treatments with Emergency Use Authorization status from the U.S.

Treatment 52

Treatment Virus Laboratories Engineering 52

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Virus 40

Virus Trials Clinical Trials Production 40

Nvidia Developer: Drug Discovery

APRIL 20, 2020

To help make the process for scientists more accessible, we’re spotlighting a few of the GPU-accelerated applications that developers can use right now in the fight against this virus. Those compounds are likely to bind to the glycosylated spike (S) protein, which is how the virus enters host cells.

Small Molecule 52

Small Molecule Virus Laboratories Science 52

The Pharma Data

MARCH 20, 2021

Accurate and timely laboratory diagnosis of COVID-19 is one of the most pivotal requirements for optimal disease management and contact tracing. The vast majority of current laboratory testing for COVID-19 is based either on detection of viral antigens, nucleic acids or on detection of virus-specific antibodies in the sera of patients.

Virus 52

Virus Assay Development Laboratories RNA 52

The Pharma Data

DECEMBER 15, 2020

The Antigen ELISA is a laboratory test able to be applied in semi quantitative automatable detection of the SARS-CoV-2 nucleocapsid protein on a large scale. Based on the well-known ELISA technology, the SARS-CoV-2 Antigen assay can be performed in most diagnostic laboratory settings and automatically processed on all open ELISA platforms.

Laboratories 52

Laboratories Science Virus Marketing 52

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. He continued: “CBASS cyclases look a lot like cGAS, so they have to be sensing something.

RNA 59

RNA Immune Response DNA Molecular Biology 59

The Pharma Data

NOVEMBER 1, 2020

The BD Veritor Plus System is already in use across Europe to detect Influenza A+B, Respiratory Syncytial Virus (RSV), and Group A Strep. The test has been authorized by FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories. Food and Drug Administration (FDA).

Laboratories 52

Laboratories Virus FDA Government 52

The Pharma Data

JANUARY 21, 2021

Researchers randomized patients to either 4,200 mg of IV-administered bamlanivimab or placebo and saw that after eight weeks of participant follow-up, the 965 participants who tested negative for the virus at baseline saw a 57 percent lower frequency of symptomatic COVID-19 in the drug arm compared to the placebo arm.

Nurses 52

Nurses Research Laboratories Laboratories Virus 52

The Pharma Data

MARCH 14, 2021

During the production of the vaccine more than 60 quality tests are conducted by AstraZeneca, its partners and by more than 20 independent testing laboratories. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Vaccine 52

Vaccine Virus Licensing Licensing 52

The Pharma Data

JULY 12, 2021

The Phase 3 portion of the global MOVe-OUT trial studying molnupiravir in non-hospitalized adult patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes is underway. If successful, molnupiravir could help address the continued urgent need for therapeutics.”. About Molnupiravir.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

SEPTEMBER 1, 2020

Point of care testing increases access to high quality diagnostics solutions for the detection of a current SARS-CoV-2 infection, regardless of laboratory testing infrastructure or patient mobility. This is highly beneficial where timely decisions are needed or laboratory testing is inaccessible.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

Drug Target Review

SEPTEMBER 28, 2023

For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus. These are synthetic, not the live virus, so do not pose a risk of infection. We knew that we had the technology and ability to develop synthetic controls for SARS-CoV-2.

DNA 116

DNA Organic Chemistry Science Virus 116

The Pharma Data

OCTOBER 19, 2020

Spectrum’s self-contained saliva collection kit provides critical sample consistency while suspending and neutralizing viral RNA transcripts completely inactivating the live virus. Additionally, the SDNA-1000 stabilizes and protects saliva samples making both sample collection and transport for COVID-19 testing easy. Photo: Business Wire).

RNA 52

RNA DNA Engineering Virus 52

Advarra

AUGUST 8, 2023

Viral infection involves the transfer of the virus’ genetic material to host cells, making viruses ideal tools for gene transfer—once the genes responsible for viral replication and disease are removed.

Therapies 52

Therapies Research Engineering Clinical Research 52

Alta Sciences

OCTOBER 7, 2024

Bookmark this list for easy reference: [Scientific Poster] Historical Review of In-Life Data From Studies Utilizing AAVs for Gene Therapy [Scientific Poster] Incidence of Neutralizing Adeno-Associated Viral Antibody Subtypes in Cynomolgus Monkeys of Cambodian, Mauritius, and Philippines Origins ​​​​ [Scientific Poster] The Nonhuman Primate Model of (..)

Therapies 40

Therapies Research Laboratories Virus 40

The Pharma Data

APRIL 22, 2023

According to Kirimanjeswara, the spike protein of the SARS-CoV-2 virus is under heavy selection pressure, which can result in mutations that drive the emergence of new variants. “The virus would have to undergo too many mutations to be able to escape this T-cell-mediated immunity, so that is one advantage,” said Kirimanjeswara.

Vaccine 40

Vaccine Virus Laboratories Immune Response 40

The Pharma Data

SEPTEMBER 30, 2021

With user permission, the results may be shared with participating laboratories around the globe in a secure environment. If they select to share data, they will contribute to electronic dashboard visualisations of global data revealing the daily changes in the way the pandemic is progressing and how the virus is changing.

Research 52

Research Virus Government Laboratories 52

Agency IQ

SEPTEMBER 6, 2023

The EPA’s Office of Pesticide Programs (OPP) Microbiology Laboratory Branch (MLB) has established standardized testing methods and procedures for pesticide products used to kill or suppress the growth of pathogenic microorganisms on inanimate objects and hard surfaces. One was for use against viruses and one was for combating bacteria.

Production 40

Production Virus Long-Term Care Facilities Laboratories 40

Alta Sciences

MARCH 1, 2024

The new cells are then grown in high numbers in a laboratory and then are re-administered to the patient, where the genetically modified cells will attack more specific cancer cells. This technology extensively utilizes immunofluorescence and flow cytometry technology, which is a platform offered in our laboratories.

Therapies 52

Therapies Laboratories Molecular Biology RNA 52

The Pharma Data

OCTOBER 27, 2021

“The main finding in our study is that the equine hyperimmune globulins antibodies developed against the spike protein of the ancestral SARS-CoV-2 had high neutralizing action against the new variants of the virus, such as the gamma strain. . The scientists are confident of the efficiency of the new product.

Clinical Trials 52

Clinical Trials Virus Production Treatment 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 could provide a much-needed treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thus slowing the spread of the global pandemic. and Roche will be responsible for distribution outside the U.S. “We

Clinical Trials 52

Clinical Trials Virus Trials Treatment 52

Drug Target Review

SEPTEMBER 8, 2023

His laboratory plans to use a “systems biochemistry” approach to further study the role of cytoplasmic and nuclear RARα in T cell activation and differentiation. The ability to transmit this signal to the cell nucleus is pivotal, as it triggers gene expression changes that convert the T cell into a combat-ready entity.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

APRIL 15, 2022

These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group. About the Pfizer-BioNTech Laboratory Study. The neutralizing GMT against the wild-type virus was 2153 (after three doses), compared to 335 after two doses.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

FEBRUARY 23, 2022

For comparison, a panel of sera from volunteers in the same age range who received two doses of an already approved and highly effective mRNA vaccine displayed a GMT of 1653 units, measured simultaneously in the same laboratory. against any symptomatic COVID-19 disease in the seronegative population.

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

AUGUST 7, 2020

The LY-CoV555 antibodies are infection fighting that can bind to the surface of viruses and prevent the virus infecting cells. These manufactured antibodies have been developed and manufactured by Eli Lilly and Company ’s Lilly Research Laboratories in a partnership with AbCellera.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

SEPTEMBER 16, 2020

Priti Patel: “The government has been consistently increasing testing capacity, but also laboratory capacity” The home secretary is correct that government data shows that both testing capacity and laboratory capacity have increased considerably since the beginning of the pandemic.

Government 52

Government International Laboratories Hospitals 52